1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vaxcyte, Inc.
  6. News
  7. Summary
    PCVX   US92243G1085

VAXCYTE, INC.

(PCVX)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
25.27 USD   +2.97%
05/10TRANSCRIPT : Vaxcyte, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 02:40 PM
CI
05/09VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/09Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VAXCYTE, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

01/13/2022 | 05:18pm EDT
Item 8.01. Other Events


Underwriting Agreement

On January 12, 2022, Vaxcyte, Inc. ("Vaxcyte") entered into an underwriting agreement (the "Underwriting Agreement") with BofA Securities, Inc., Jefferies LLC and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale (the "Offering") of 2,500,000 shares of its common stock, par value $0.001 per share, at a price to the public of $20.00 per share, and pre-funded warrants to purchase 2,500,000 shares of its common stock at a price to the public of $19.999 per underlying share. Pursuant to the Underwriting Agreement, the Underwriters have agreed to purchase the shares of common stock from Vaxcyte at a price of $18.80 per share and the pre-funded warrants at a price of $18.799 per underlying share. The net proceeds to Vaxcyte from this Offering are expected to be approximately $93.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Vaxcyte. The Underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock. All of the shares and pre-funded warrants in the Offering are being sold by Vaxcyte. The closing of the Offering is expected to occur on or about January 18, 2022, subject to the satisfaction of customary closing conditions.

The Offering is being made pursuant to our effective registration statement on Form S-3 (Registration Statement No. 333-257622), as previously filed with the Securities and Exchange Commission and a related prospectus and prospectus supplement.

The Underwriting Agreement contains customary representations, warranties and agreements by Vaxcyte, customary conditions to closing, indemnification obligations of Vaxcyte and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement.

The Underwriting Agreement is filed as Exhibit 1.1 hereto, and the form of pre-funded warrant is filed as Exhibit 4.1 hereto. The foregoing descriptions of the terms of the Underwriting Agreement and the pre-funded warrants are qualified in their entirety by reference to such exhibits hereto. A copy of the opinion of Cooley LLP relating to the legality of the issuance and sale of the securities in the Offering is attached as Exhibit 5.1 hereto.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits




Exhibit
Number       Description

 1.1           Underwriting Agreement, dated January 12, 2022

 4.1           Form of Pre-Funded Warrant

 5.1           Opinion of Cooley LLP

23.1           Consent of Cooley LLP (contained in Exhibit 5.1)

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about VAXCYTE, INC.
05/10TRANSCRIPT : Vaxcyte, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-..
CI
05/09VAXCYTE, INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
05/09Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update
GL
05/09Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/03Vaxcyte to Participate in Upcoming Investor Conferences in May
GL
05/03Vaxcyte to Participate in Upcoming Investor Conferences in May
GL
04/20INSIDER SELL : Vaxcyte
MT
04/18VAXCYTE, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
04/12TRANSCRIPT : Vaxcyte, Inc. Presents at Needham 21st Annual Healthcare Conference, Apr-12-2..
CI
04/07INSIDER SELL : Vaxcyte
MT
More news